Zacks: Analysts Expect Mirum Pharmaceuticals (NASDAQ:MIRM) to Announce -$0.46 EPS

Wall Street brokerages expect Mirum Pharmaceuticals (NASDAQ:MIRM) to post earnings per share of ($0.46) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Mirum Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.52) and the highest estimate coming in at ($0.39). The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Mirum Pharmaceuticals will report full year earnings of ($1.82) per share for the current financial year, with EPS estimates ranging from ($2.14) to ($1.50). For the next year, analysts anticipate that the firm will report earnings of ($2.12) per share, with EPS estimates ranging from ($3.11) to ($1.13). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Mirum Pharmaceuticals.

Several brokerages have commented on MIRM. Roth Capital began coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued a “buy” rating and a $33.00 price objective for the company. Guggenheim began coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued a “buy” rating and a $18.00 price objective for the company. Raymond James began coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued an “outperform” rating and a $28.00 price objective for the company. Citigroup began coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Evercore ISI began coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued an “outperform” rating and a $25.00 price objective for the company. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $25.00.

Shares of Mirum Pharmaceuticals stock traded up $0.64 during trading on Friday, reaching $14.09. The company’s stock had a trading volume of 603 shares, compared to its average volume of 70,112. Mirum Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $15.50.

In related news, major shareholder Holdings A/S Novo purchased 575,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were purchased at an average price of $15.00 per share, with a total value of $8,625,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Patrick J. Heron purchased 450,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $6,750,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 1,357,000 shares of company stock worth $20,355,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Further Reading: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.